PT - JOURNAL ARTICLE AU - Keyvan Heydari AU - Sahar Rismantab AU - Amir Shamshirian AU - Parisa Lotfi AU - Nima Shadmehri AU - Pouya Houshmand AU - Mohammad Zahedi AU - Danial Shamshirian AU - Sahar Bathaeian AU - Reza Alizadeh-Navaei TI - Clinical and Paraclinical Characteristics of COVID-19 patients: A systematic review and meta-analysis AID - 10.1101/2020.03.26.20044057 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.26.20044057 4099 - http://medrxiv.org/content/early/2020/03/30/2020.03.26.20044057.short 4100 - http://medrxiv.org/content/early/2020/03/30/2020.03.26.20044057.full AB - Introduction Recently, a new strain of coronaviruses, which originated from Wuhan City, Hubei Province, China has been identified. According to the high prevalence of new coronavirus, further investigation on the clinical and paraclinical features of this disease seems essential. Hence, we carried out this systematic review and meta-analysis to figure out the unknown features.Methods This study was performed using databases of Web of Science, Scopus and PubMed. We considered English cross-sectional and case-series papers which reported clinical, radiological, and laboratory characteristics of patients with COVID-19. We used STATA v.11 and random effect model for data analysis.Results In the present meta-analysis, 32 papers including 49504 COVID-19 patients were studied. The most common clinical symptoms were fever (84%), cough (65%) and fatigue (42%), respectively. The most common radiological and paraclinical features were bilateral pneumonia (61%), ground-glass opacity (50%), thrombocytopenia (36%) and lymphocytopenia (34%). The study also showed that the frequency of comorbidities and early symptoms was higher in critically severe patients. Moreover, we found the overall mortality rate of three percent.Conclusion According to that there are many cases without Computed Tomography Scan findings or clear clinical symptoms, it is recommended to use other confirming methods such RNA sequencing in order to identification of suspicious undiagnosed patients. Moreover, while there is no access to clinical and paraclinical facilities in in public places such as airports and border crossings, it is recommended to consider factors such as fever, cough, sputum and fatigue.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe have no funds for this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in data bases mentioned in the search strategy.